ArticleBJOG : an international journal of obstetrics and gynaecology2023
Population-based genetic testing for cancer susceptibility genes: quo vadis?
Article in BJOG : an international journal of obstetrics and gynaecology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-Analysis of CYP1A1 MspI and Ile462Val Polymorphisms in Cancer Susceptibility Among Different Ethnic Populations.Environmental and molecular mutagenesis · 2026Pooled it
- Financing and health system capacity for precision medicine in Asia: a six country landscape analysis.Health affairs scholar · 2026Review
- Health-related quality of life after risk-reducing hysterectomy (PRESCORES): a cross-sectional study.EClinicalMedicine · 2026Article
- Assessing Willingness to Pay for Genetic Testing Among Adults: A Cross-Sectional Study Using Data from the Omnibus Survey 2022.Journal of personalized medicine · 2026Article
- Observational
- Estimands for Clinical Effectiveness of Risk-Reducing Early Salpingectomy in Women With High Risk of Ovarian Cancer.JAMA network open · 2025Observational
- Defining Lifetime Risk Thresholds for Breast Cancer Surgical Prevention.JAMA oncology · 2025Article
- The Role of Cytoreductive Surgery in Platinum-Resistant Ovarian Cancer (PROC): A Systematic Review.Cancers · 2025Review
- 'Why Don't We Get Counselling?': Comparing NICE Guidelines for Morphological and Genetic Cancer Risk Diagnoses.Cancer medicine · 2025Article
- Understanding the prevalence of germline oncogenic biomarker variants across the Indian population.Journal of genetics · 2025Article
- Economic Evaluation of Population-Based BRCA1 and BRCA2 Testing in Canada.JAMA network open · 2024Article
- Online Provision ofCancers · 2024Article
- Utility Scores for Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy: Mapping to EQ-5D.Cancers · 2024Article
- Screening and prevention of ovarian cancer.The Medical journal of Australia · 2024Review
- Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.JAMA network open · 2024Article
- Combined population genomic screening for three high-risk conditions in Australia: a modelling study.EClinicalMedicine · 2023Article
- Population-based genetic testing for cancer susceptibility genes: quo vadis?BJOG : an international journal of obstetrics and gynaecology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.